Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-01

Study Completion Date

2025-11-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a proof-of-concept trial of vonafexor safety, its effects on kidney function in subjects with at risk of progression Alport syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

NCT06939816

Chronic Kidney Disease Stage 2 Chronic Kidney Disease Stage 3 Metabolic Dysfunction-Associated Steatohepatitis

RECRUITING PHASE2

Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT02115659

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

UNKNOWN PHASE3

A Renal Impairment Study for PF-04965842

NCT03660241

Renal Impairment

COMPLETED PHASE1

A Study of RG-012 in Subjects With Alport Syndrome

NCT03373786

Alport Syndrome

COMPLETED PHASE1

Study of ALXN2050 in Participants With Renal Impairment

NCT04623710

Renal Impairment Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter study and several clinical sites and countries will be involved.

This single arm, fixed dose escalation, open-label, non-randomized study will evaluate three dose levels of vonafexor on safety, tolerability and their effect on kidney function and renal biomarkers in 20 patients with AS at risk of progression.

The total duration of study for a participant will be up to 40 weeks and include a screening period, a treatment period of 24 weeks and a follow-up period of 12 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alport Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single arm fixed dose escalation

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single arm fixed dose escalation

This is a single arm fixed dose escalation with three dose levels of vonafexor, all QD.

Group Type EXPERIMENTAL

Vonafexor

Intervention Type DRUG

* One tablet of a low dose of vonafexor QD from Day 1 to Week 4
* One tablet of a medium dose of vonafexor QD from Week 5 to Week 8
* One tablet of a high dose of vonafexor QD from Week 9 to Week 24

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vonafexor

* One tablet of a low dose of vonafexor QD from Day 1 to Week 4
* One tablet of a medium dose of vonafexor QD from Week 5 to Week 8
* One tablet of a high dose of vonafexor QD from Week 9 to Week 24

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EYP001a

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent (also for legal representatives, as applicable in the US for under eighteen patients).
* Has confirmed diagnosis of Alport syndrome: clinical diagnosis (haematuria, family history, hearing loss, ocular change) OR a kidney biopsy showing glomerular basement membrane abnormalities consistent with AS, AND Genetic confirmation of AS.
* Has eGFR between ≥ 30 and \< 90 ml/min/1.73m2.
* Has increased albuminuria criteria i.e. UACR ≥ 300 mg/g.
* If on an angiotensin converting enzyme inhibitor (ACEi) and/or angiotensin receptor blocker (ARB), should be on a stable well tolerated treatment during at least the 60 days prior D1.
* If on Sodium-Glucose Transport Protein 2 (SGLT2), should be on stable well tolerated treatment with SGLT2 during at least 60 days prior D1.
* If patient has a history of arterial hypertension, should be on stable anti-hypertensive therapy for at least 60 days prior to D1 and deemed controlled by the investigator at screening and D1.
* Sexually active female subjects of childbearing potential and sexually mature male subjects must use two acceptable effective methods of contraception for the entire duration of the study and for at least 6 weeks after last dose.
* Has negative results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, and human immunodeficiency virus (HIV).
* Is able to understand all study procedures in the informed consent form (ICF) and willing to comply with all aspects of the protocol.

Exclusion Criteria

* Is an employee of a site, clinical research organization, vendor, or sponsor involved with this study.
* Is pregnant or breastfeeding.
* Has participated in any investigational drug study within 60 days prior to D1.
* Any clinically significant illness within 30 days before D1 or surgical or medical condition (other than Alport syndrome) that could interfere with the subject's study compliance; confound the study results; impact subject safety.
* Any history of active malignancy within the last 1 year before D1.
* Any other condition or circumstance that, in the opinion of the investigator, may make the subject unlikely to complete the study or comply with study procedures and requirements, or may pose a risk to the subject's safety and well-being.
* Has a history of an allergic condition that required the prescription of an emergency epinephrine injection (such as the EpiPen® Auto-Injector).
* Any prohibited co-medications within 30 days prior D1.
* Has ALT or AST above near normal (\>1.5×ULN) at baseline.
* Are at high risk for atherosclerotic cardiovascular disease (ASCVD) risk, with an LDL-C level \> 160 mg/dL (4.15 mmol/L) and subjects at intermediate risk for ASCVD risk, with a LDL-C level \> 190 mg/dL (4.91 mmol/L).
* Has moderate or severe hepatic impairment (Child-Pugh score B or C).
* Is taking CYP3A4/5 inhibitors or inducers.

Minimum Eligible Age

16 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No